Nitrase Therapeutics: Funding, Investors & Team (Sep 2026)
Nitrase Therapeutics is a platform company developing drugs against a newly identified class of enzymes called Nitrases, initially targeting Parkinson’s disease. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases such as Parkinson’s. While the initial focus is on Parkinson's disease, the company aims to expand its proprietary platform to include other disease indications.
Nitrase Therapeutics has raised $7.0M across 1 funding round on record, the most recent a Series A of $7.0M announced in Nov 2021.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Nitrase Therapeutics Company Profile and Key Stats
Latest funding round on record: Nov 2021.
Nitrase Therapeutics Funding Rounds
Nitrase Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Nitrase Therapeutics Funding Compared to Other Biotechnology Startups
Nitrase Therapeutics' latest round of $7.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Nitrase Therapeutics in Biotechnology and Jackson
Companies Similar to Nitrase Therapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Nitrase Therapeutics Funding FAQs
What does Nitrase Therapeutics do?
Nitrase Therapeutics is a platform company developing drugs against a newly identified class of enzymes called Nitrases, initially targeting Parkinson’s disease. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases such as Parkinson’s. While the initial focus is on Parkinson's disease, the company aims to expand its proprietary platform to include other disease indications.
How much funding has Nitrase Therapeutics raised?
Nitrase Therapeutics has raised $7.0M across 1 round on record. The most recent is a Series A of $7.0M announced in Nov 2021.
When did Nitrase Therapeutics last raise funding?
Nitrase Therapeutics' most recent funding round on record is a Series A of $7.0M, announced in Nov 2021.
Who is the CEO of Nitrase Therapeutics?
Pierre Beaurang is listed as CEO at Nitrase Therapeutics.
Where is Nitrase Therapeutics headquartered?
Nitrase Therapeutics is based in Jackson, Mississippi, United States.
How many employees does Nitrase Therapeutics have?
Nitrase Therapeutics is in the 11-50 employee band.
How does Nitrase Therapeutics' funding compare to other Biotechnology startups?
Nitrase Therapeutics' latest round of $7.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Nitrase Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Nitrase Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.